Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 29;21(1):812.
doi: 10.1186/s13063-020-04744-x.

Prophylactic prednisolone for the prevention of early and intermediate adverse effects of radioactive iodine therapy in patients with thyroid cancer: study protocol for a single-centre, phase II/III, randomized, double-blinded, placebo-controlled clinical trial

Umesh Jayarajah  1   2 , Mahilal Wijekoon  3 , Sanjeewa A Seneviratne  4
Affiliations

Prophylactic prednisolone for the prevention of early and intermediate adverse effects of radioactive iodine therapy in patients with thyroid cancer: study protocol for a single-centre, phase II/III, randomized, double-blinded, placebo-controlled clinical trial

Umesh Jayarajah et al. Trials. .

Abstract

Background: Radioactive iodine (RAI) therapy is the standard adjuvant treatment for differentiated thyroid cancer (i.e. papillary and follicular). RAI is associated with troublesome early, intermediate and late adverse effects. Although glucocorticoids are used for the management of these adverse effects, there is little evidence regarding the effectiveness of prophylactic glucocorticoids to prevent these complications. This trial will evaluate the efficacy of a short course of prophylactic glucocorticoids in the prevention of adverse effects of RAI treatment in patients with differentiated thyroid cancer.

Methods: A phase II/III, single-centre, randomized, double-blinded, placebo-controlled, parallel-arm clinical trial will be conducted. Patients with differentiated thyroid cancer who are referred to RAI therapy at the National Cancer Institute, Sri Lanka, will be randomized into two arms consisting of 200 patients each. The experimental group will receive prophylactic oral prednisolone 0.5 mg/kg and omeprazole 20 mg single dose 6 h before RAI therapy followed by oral prednisolone 0.5 mg/kg and omeprazole 20 mg daily for 3 days. The control group will receive oral placebo and omeprazole 20 mg single dose 6 h before RAI therapy followed by oral placebo and omeprazole 20 mg daily for 3 days. Clinically significant adverse effects assessed as related to RAI as well as prednisolone therapy and the quality of life parameters will be compared between the two groups.

Discussion: If proven beneficial, this intervention can be incorporated into the standard practice to reduce early and intermediate adverse effects of RAI for thyroid cancer with a potential improvement of quality of life.

Trial registration: Sri Lanka Clinical Trials Registry SLCTR/2020/009 . Registered prospectively on 23 February 2020. Items of the WHO Trial Registration Data Set are provided in the supplementary file.

Keywords: Adverse effects; Prednisolone; Radioactive iodine therapy; Randomized control trial; Study protocol; Thyroid cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

References

    1. Seidlin S, Marinelli L, Oshry E. Radioactive iodine therapy: effect on functioning metastases of adenocarcinoma of the thyroid. J Am Med Assoc. 1946;132(14):838–847. doi: 10.1001/jama.1946.02870490016004. - DOI - PubMed
    1. Van Nostrand D. The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer. Thyroid. 2009;19(12):1381–1391. doi: 10.1089/thy.2009.1611. - DOI - PubMed
    1. Jayarajah U, Nagodavithane K, Basnayake O, Seneviratne S. Surgical management of papillary thyroid cancer: review of current evidence and consensus. Sri Lanka J Surg. 2019;37(4):18–23.
    1. Lu L, Shan F, Li W, Lu H. Short-term side effects after radioiodine treatment in patients with differentiated thyroid cancer. Biomed Res Int. 2016;2016:5. - PMC - PubMed
    1. Lee SL. Complications of radioactive iodine treatment of thyroid carcinoma. J Natl Compr Cancer Netw. 2010;8(11):1277–1287. doi: 10.6004/jnccn.2010.0094. - DOI - PubMed

Publication types